# Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study

> **NCT07025460** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Gangnam Severance Hospital** · enrollment: 40 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT07025460
- **Lead sponsor:** Gangnam Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-19
- **Primary completion:** 2024-10-17
- **Final completion:** 2026-01-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07025460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07025460, "Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07025460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*